Literature DB >> 23851977

A tetracycline-regulated cell line produces high-titer lentiviral vectors that specifically target dendritic cells.

Paul D Bryson1, Chupei Zhang, Chi-Lin Lee, Pin Wang.   

Abstract

Lentiviral vectors (LVs) are a powerful means of delivering genetic material to many types of cells. Because of safety concerns associated with these HIV-1 derived vectors, producing large quantities of LVs is challenging. In this paper, we report a method for producing high titers of self-inactivating LVs. We retrovirally transduce the tet-off stable producer cell line GPR to generate a cell line, GPRS, which can express all the viral components, including a dendritic cell-specific glycoprotein, SVGmu. Then, we use concatemeric DNA transfection to transfect the LV transfer plasmid encoding a reporter gene GFP in combination with a selectable marker. Several of the resulting clones can produce LV at a titer 10-fold greater than what we achieve with transient transfection. Plus, these viruses efficiently transduce dendritic cells in vitro and generate a strong T cell immune response to our reporter antigen. This method may be a good option for producing strong LV-based vaccines for clinical studies of cancer or infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23851977      PMCID: PMC3727697          DOI: 10.3791/50606

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  23 in total

1.  Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.

Authors:  H Bobby Gaspar; Kathryn L Parsley; Steven Howe; Doug King; Kimberly C Gilmour; Joanna Sinclair; Gaby Brouns; Manfred Schmidt; Christof Von Kalle; Torben Barington; Marianne A Jakobsen; Hans O Christensen; Abdulaziz Al Ghonaium; Harry N White; John L Smith; Roland J Levinsky; Robin R Ali; Christine Kinnon; Adrian J Thrasher
Journal:  Lancet       Date:  2004 Dec 18-31       Impact factor: 79.321

2.  A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors.

Authors:  Adam S Cockrell; Hong Ma; Kailing Fu; Thomas J McCown; Tal Kafri
Journal:  Mol Ther       Date:  2006-03-03       Impact factor: 11.454

3.  A packaging cell line for lentivirus vectors.

Authors:  T Kafri; H van Praag; L Ouyang; F H Gage; I M Verma
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

4.  Continuous high-titer HIV-1 vector production.

Authors:  Yasuhiro Ikeda; Yasuhiro Takeuchi; Francisco Martin; Francois-Loic Cosset; Kyriacos Mitrophanous; Mary Collins
Journal:  Nat Biotechnol       Date:  2003-04-07       Impact factor: 54.908

5.  Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells.

Authors:  Blair L Strang; Yasuhiro Takeuchi; Thomas Relander; Johan Richter; Ranbir Bailey; David A Sanders; Mary K L Collins; Yasuhiro Ikeda
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Retrovirus producer cell line metabolism: implications on viral productivity.

Authors:  A S Coroadinha; P M Alves; S Sá Santos; P E Cruz; O-W Merten; M J T Carrondo
Journal:  Appl Microbiol Biotechnol       Date:  2006-04-06       Impact factor: 4.813

7.  Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.

Authors:  Lili Yang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-09       Impact factor: 11.205

8.  Engineered lentivector targeting of dendritic cells for in vivo immunization.

Authors:  Lili Yang; Haiguang Yang; Kendra Rideout; Taehoon Cho; Kye Il Joo; Leslie Ziegler; Abigail Elliot; Anthony Walls; Dongzi Yu; David Baltimore; Pin Wang
Journal:  Nat Biotechnol       Date:  2008-02-24       Impact factor: 54.908

9.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

10.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Maurilio Ponzoni; Cynthia Bartholomae; Lucia Sergi Sergi; Fabrizio Benedicenti; Alessandro Ambrosi; Clelia Di Serio; Claudio Doglioni; Christof von Kalle; Luigi Naldini
Journal:  Nat Biotechnol       Date:  2006-05-28       Impact factor: 54.908

View more
  5 in total

1.  Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation.

Authors:  Jocelyn T Kim; Yarong Liu; Rajan P Kulkarni; Kevin K Lee; Bingbing Dai; Geoffrey Lovely; Yong Ouyang; Pin Wang; Lili Yang; David Baltimore
Journal:  Sci Immunol       Date:  2017-07-21

2.  Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.

Authors:  Paul D Bryson; Xiaolu Han; Norman Truong; Pin Wang
Journal:  Vaccine       Date:  2017-09-12       Impact factor: 3.641

Review 3.  An Update on the HIV DNA Vaccine Strategy.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  Vaccines (Basel)       Date:  2021-06-05

4.  Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.

Authors:  Peirong Hu; Yedda Li; Mark S Sands; Thomas McCown; Tal Kafri
Journal:  Mol Ther Methods Clin Dev       Date:  2015-07-22       Impact factor: 6.698

5.  Immunogenicity of targeted lentivectors.

Authors:  Cleo Goyvaerts; De Groeve Kurt; Sandra Van Lint; Carlo Heirman; Jo A Van Ginderachter; Patrick De Baetselier; Geert Raes; Kris Thielemans; Karine Breckpot
Journal:  Oncotarget       Date:  2014-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.